All GLG News Analyses Filed Under: Orthopaedics
Posted September 21, 2007
Reclast sounds promising (Novartis, Healthcare)
Analysis of: First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival | www.pipelinereview.com
Author: GLG Member Program Contributor
Reclast sounds like a promising new drug. Although many osteoporosis drugs are currently on the market, this is the only one that has shown such a dramatic decrease in the recurrence of fractures, which is definitely a plus. In terms of compliance, it is also very innovative, because...
Posted September 20, 2007
great but with a catch
Analysis of: First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival | www.pipelinereview.com
Author: GLG Member Program Contributor
This is a very promising study. If post-marketing does not show a major problem with new onset A-fib., this will be a great therapy.
Posted September 18, 2007
Reclast (Novartis) a Winner!!
Analysis of: Novartis Drug Curbs Repeat Hip Fractures | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Novartis Drug Curbs Repeat Hip Fractures | online.wsj.com
Author: GLG Member Program Contributor
Yearly infusions of a Zometa relative- Reclast, in elderly patients after hip fracture, prevent repeat fractures and prolong survival. Yes!! Looks like a reasonable study and this yearly IV agent is certainly more tolerable than oral bisphosphonates with the associated killer heart burn and need to...
Posted September 18, 2007
Is CYT645 a Potential Treatment for Osteoporosis: Who Could Possibly Know?
Analysis of: Cytopia Compounds show potential as treatment for bone loss | www.cytopia.com.au
Author: GLG Member Program Contributor
Analysis of: Cytopia Compounds show potential as treatment for bone loss | www.cytopia.com.au
Author: GLG Member Program Contributor
The press -- at least that segment of medical media that covers biotechnology -- has seemingly picked up a press release issued by Cytopia and run with it. The press release proclaims how Cytopia's compound CYT645, an inhibitor of an enzyme that appears to be involved in bone resorption, may have potential...
Posted August 20, 2007
Vertebroplasty vs kyphoplasty vs arcuoplasty
Analysis of: Medtronic Buys Kyphon For $3.9 Billion | www.forbes.com
Author: Luc Jasmin, Attending Neurosurgeon and a Research Scientist Cedars-Sinai Medical Center
Vertebroplasty vs kyphoplasty vs arcuoplasty
Analysis of: Medtronic Buys Kyphon For $3.9 Billion | www.forbes.com
Author: Luc Jasmin, Attending Neurosurgeon and a Research Scientist Cedars-Sinai Medical Center
Will the recent purchase of Kyphon by Medtronic signals the end of kyphoplasty? No because arcuoplasty does not restore vertebral height. Vertebroplasty, kyphoplasty and arcuoplasty essentially achieve the same goals, which brings up the question, do we need all three techniques? Arcuoplasty is the...
Posted August 13, 2007Xiaflex will dramatically replace surgery
Analysis of: The Journal of Hand Surgery Publishes Initial Phase III Data on Xiaflex (formerly known as AA4500), Auxilium's Investigational Treatment for Patients with Dupuytren's Contracture | pharmalive.com
Author: Keith Denkler, Associate Clinical Professor of Plastic Surgery UNIVERSITY OF CALIFORNIA SAN FRANCISCO
The efficacy of Xiaflex to not only open up the bent fingers of Dupuytren's, but its ability to diminish recurrence will dramatically decrease surgery rate for Dupuytren's.
Posted August 8, 2007
studies of low back pain therapy lead to mixed findings
Analysis of: Statistical Significance Versus Clinical Importance: Trials on Exercise Therapy for Chronic Low Back Pain as Example | www.ncbi.nlm.nih.gov
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director Spinal and Neurosurgical Institute
studies of low back pain therapy lead to mixed findings
Analysis of: Statistical Significance Versus Clinical Importance: Trials on Exercise Therapy for Chronic Low Back Pain as Example | www.ncbi.nlm.nih.gov
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director Spinal and Neurosurgical Institute
Low back pain is a major public health problem. While there is no single therapy that can be prescribed to every patient with this problem, the ubiquitous prescribing of physical therapy is frequently misguided. The causes of low back pain are myriad, and the treatment algorithm needs to...
Posted August 7, 2007
Novel Oral Tablet Option For the treatment of Bone Diseases
Analysis of: Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease | www.pipelinereview.com
Author: Kuldeepak Sharma, President/Pharmaceutical Consultant Dr. Kuldeepak Sharma
Novel Oral Tablet Option For the treatment of Bone Diseases
Analysis of: Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease | www.pipelinereview.com
Author: Kuldeepak Sharma, President/Pharmaceutical Consultant Dr. Kuldeepak Sharma
As a pharmaceutical consultant, I think this IND will be novel groundbreaking treatment option for the treatment of bone diseases because it is one of first oral tablet formulation that enables oral absorption of gallium nitrate injection for treatment of cancer-related hypocalcaemia. Also this is unique...
Posted August 7, 2007
dupuytrens contracture
Analysis of: The Journal of Hand Surgery Publishes Initial Phase III Data on Xiaflex (formerly known as AA4500), Auxilium's Investigational Treatment for Patients with Dupuytren's Contracture | pharmalive.com
Author: David Mandel, Physician Mandel, David R Md
dupuytrens contracture
Analysis of: The Journal of Hand Surgery Publishes Initial Phase III Data on Xiaflex (formerly known as AA4500), Auxilium's Investigational Treatment for Patients with Dupuytren's Contracture | pharmalive.com
Author: David Mandel, Physician Mandel, David R Md
I am a rheumatologist and treat many pts with this condition conservativelywewill be partcipating in an upcoming clin.trial with their injectable compound that has some very unique properties to relieve the contractures and possible avoid surgery
Posted August 1, 2007
Medtronic's acquisition of Breakaway Imaging is a significant step forward
Analysis of: Medtronic to Acquire Breakaway Imaging, LLC | wwwp.medtronic.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director Spinal and Neurosurgical Institute
Previous
Page :
1 2 3 4 5 6 7 8 9 10 Next41 to
50
of 95Medtronic's acquisition of Breakaway Imaging is a significant step forward
Analysis of: Medtronic to Acquire Breakaway Imaging, LLC | wwwp.medtronic.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director Spinal and Neurosurgical Institute
Medtronic will see increased sales of their navigation platform, and probably a secondary increase in thier spinal implants as a result of the acquisition of Breakway Imaging. Sales of the O-Arm have been increasing rapidly, adding to Medtronic's sucess in the field of spinal surgery
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
CVS Escalates the Generic Price War
November 13, 2008
A closer look
November 11, 2008

